Pediatric Infuvite Multiple Vitamins

×

Overview

What is Pediatric Infuvite Multiple Vitamins?

INFUVITE PEDIATRIC (multiple vitamins injection) is a sterile product consisting of two vials provided as a single dose or as a pharmacy bulk package for intravenous use intended for administration by intravenous infusion after dilution:

INFUVITE PEDIATRIC (multiple vitamins injection) supplied as single dose consists of:

Vial 1 will provide one daily dose of 1.2 mL, 2.6 mL or 4 mL and Vial 2 will provide one daily dose of 0.3 mL, 0.65 mL or 1 mL []

INFUVITE PEDIATRIC (multiple vitamins injection) supplied as pharmacy bulk package consists of:

The mixed solution will provide many single doses [].

Each 4 mL of Vial 1 contains 10 vitamins and each 1 mL of Vial 2 contains 3 vitamins (see Table 3).

INFUVITE PEDIATRIC (multiple vitamins injection) makes available a combination of oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

INFUVITE PEDIATRIC contains no more than 30 mcg/L of aluminum (combined Vials 1 and 2).

What does Pediatric Infuvite Multiple Vitamins look like?

What are the available doses of Pediatric Infuvite Multiple Vitamins?

INFUVITE PEDIATRIC is an injection consisting of two single-dose vials labeled Vial 1 (4 mL) and Vial 2 (1 mL). For the vitamin strengths [].

INFUVITE PEDIATRIC is an injection consisting of two vials labeled Vial 1 (40 mL Fill in 50 mL Vial) and Vial 2 (10 mL). The mixed solution (50 mL) will provide thirty-three 1.5 mL single doses, fifteen 3.25 mL single doses or ten 5 mL single doses. For the vitamin strengths [].

What should I talk to my health care provider before I take Pediatric Infuvite Multiple Vitamins?

How should I use Pediatric Infuvite Multiple Vitamins?

INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition.

The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

INFUVITE PEDIATRIC is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K1, folic acid, biotin, and vitamin B12

INFUVITE PEDIATRIC is supplied as a single dose or as a pharmacy bulk package, for intravenous use intended for administration by intravenous infusion after dilution:

What interacts with Pediatric Infuvite Multiple Vitamins?

Sorry No Records found

What are the warnings of Pediatric Infuvite Multiple Vitamins?

Sorry No Records found

What are the precautions of Pediatric Infuvite Multiple Vitamins?

Sorry No Records found

What are the side effects of Pediatric Infuvite Multiple Vitamins?

Sorry No records found

What should I look out for while using Pediatric Infuvite Multiple Vitamins?

INFUVITE PEDIATRIC is contraindicated in patients who have:

What might happen if I take too much Pediatric Infuvite Multiple Vitamins?

Signs and symptoms of acute or chronic overdosage may be those of individual INFUVITE PEDIATRIC component toxicity. There is no clinical experience with INFUVITE PEDIATRIC overdosage.

How should I store and handle Pediatric Infuvite Multiple Vitamins?

Protect VISIPAQUE from direct exposure to sunlight.Store VISIPAQUE at controlled room temperature, 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].VISIPAQUE may be stored in a contrast media warmer for up to one month at 37°C (98.6°F).Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container.Protect VISIPAQUE from direct exposure to sunlight.Store VISIPAQUE at controlled room temperature, 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].VISIPAQUE may be stored in a contrast media warmer for up to one month at 37°C (98.6°F).Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container.Protect VISIPAQUE from direct exposure to sunlight.Store VISIPAQUE at controlled room temperature, 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].VISIPAQUE may be stored in a contrast media warmer for up to one month at 37°C (98.6°F).Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container.Protect VISIPAQUE from direct exposure to sunlight.Store VISIPAQUE at controlled room temperature, 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].VISIPAQUE may be stored in a contrast media warmer for up to one month at 37°C (98.6°F).Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container.How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).How Supplied:INFUVITE PEDIATRIC (multiple vitamins injection) is supplied as follows:INFUVITE PEDIATRIC (multiple vitamins injection) INFUVITE PEDIATRIC (multiple vitamins injection) Storage and Handling:Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive.Store under refrigeration 2 to 8°C (36 to 46°F).

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Non-Clinical Toxicology

INFUVITE PEDIATRIC is contraindicated in patients who have:

Drug Interactions:

It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol. The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.

Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase. The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone. Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.

The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation. Review of these case reports indicates that the patients were mainly receiving thiazide diuretics for hypertension and that tests to rule out decreased renal function secondary to hypertensive nephropathy were not often performed. In those patients in whom renal insufficiency was documented, however, the recommendation to lower the dose of allopurinol was not followed. Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected.

An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of the reported association has not been established.

Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol. However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine, and/or mechlorethamine.

Tolbutamide's conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver. The clinical significance, if any, of these observations is unknown.

Chlorpropamide's plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule. The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.

Rare reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol. Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.

INFUVITE PEDIATRIC contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in pediatric patients with renal impairment. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. To prevent aluminum toxicity periodically monitor aluminum levels with prolonged parenteral administration of INFUVITE PEDIATRIC.

The following adverse reactions are discussed in greater detail in other sections of the labeling.

The following adverse reactions have been identified during postapproval use of INFUVITE PEDIATRIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: